Nektar Therapeutics (NKTR)
49.16
-4.14
(-7.77%)
USD |
NASDAQ |
Dec 16, 16:00
49.09
-0.07
(-0.14%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (Annual): 119.64M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Amgen, Inc. | 5.676B |
| Amicus Therapeutics, Inc. | 109.36M |
| Eli Lilly & Co. | 10.99B |
| Rigel Pharmaceuticals, Inc. | 23.38M |
| Zevra Therapeutics, Inc. | 35.71M |